NIH R01 · 2024
Abstract - Our laboratories have focused on understanding how the EGF receptor (EGFR) and its signaling partner, the GTP-binding/protein crosslinking enzyme tranglutaminase-2 (TGase-2), contribute to aggressive cancers, and discovered that TGase-2 enhances EGFR signaling by blocking its degradation by c-Cbl. The goals of CA201402 were then to examine whether TGase-2 provides a similar protective effect for the EGFR oncogenic variant, EGFRvIII, in glioma stem cells (GSCs), and if these proteins are important for the actions of their extracellular vesicles (EVs). Our efforts have resulted in a number of new discoveries, which form the basis of this renewal application. These include the…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.